Agios Pharmaceuticals Quarterly Cash Flow Statement
NASDAQ: AGIOHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Agios Pharmaceuticals free cash flow
In the quarter ended Jun 30, 2026, Agios Pharmaceuticals generated -$57.3 million of operating cash flow and spent $1.2 million on capital expenditures. That left free cash flow of -$58.5 million, a free-cash-flow margin of -130.8% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Agios Pharmaceuticals cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -100.70M | -99.11M | -108.04M | -103.43M | -112.02M | -89.29M | -96.52M | 947.91M | -96.12M | -81.55M | -95.94M | -91.32M |
| Net Income growth (YoY) | — | — | — | -110.91% | — | — | — | — | — | — | -362.66% | — |
| Stock-Based Compensation | 15.94M | 15.54M | 14.12M | 12.38M | 14.69M | 11.36M | 10.90M | 11.14M | 11.56M | 9.23M | 13.81M | 9.08M |
| Change in Working Capital | -853.00K | -15.17M | -8.52M | 2.10M | -602.00K | -6.17M | -3.88M | -108.00K | 2.24M | -7.30M | -3.58M | -555.00K |
| Operating Cash Flow | -57.31M | -118.92M | -96.21M | -88.15M | -77.12M | -111.49M | -133.17M | -84.22M | -72.59M | -99.87M | -72.49M | -61.64M |
| Capital Expenditures | -1.21M | -769.00K | -1.12M | -1.55M | -875.00K | -766.00K | -967.00K | -419.00K | -158.00K | -141.00K | -234.00K | -369.00K |
| Investing Cash Flow | 40.21M | 141.31M | 90.08M | 95.56M | 78.97M | 112.59M | -49.16M | 250.79M | 37.24M | 124.56M | 95.51M | 39.34M |
| Financing Cash Flow | 3.15M | 2.08M | 2.56M | 4.43M | 65.00K | 1.62M | 4.84M | 2.64M | 1.10M | 5.86M | 847.00K | 1.88M |
| Net Change in Cash | -13.95M | 24.47M | -3.58M | 11.84M | 1.91M | 2.72M | -177.48M | 169.21M | -34.25M | 30.56M | 23.87M | -20.42M |
| Free Cash Flow | -58.52M | -119.69M | -97.33M | -89.71M | -78.00M | -112.25M | -134.13M | -84.64M | -72.75M | -100.01M | -72.72M | -62.01M |
This table shows 12 quarterly periods of Agios Pharmaceuticals's cash flow statement, from Q2 2026 back to Q3 2023, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow AGIO's reporting calendar. What is a cash flow statement?